RedHill Biopharma Corporate Presentation 2016

Emerging biopharmaceutical company focused on development and commercialization of late clinical-stage, orally-administered small molecule drugs for gastrointestinal, inflammatory diseases and cancer. Features robust pipeline with three ongoing Phase III programs including RHB-104 for Crohn's disease and RHB-105 for H. pylori infection with recent Phase III primary endpoint success.